Q4 2015 - 60% GROWTH AND INCREASED OPERATING MARGIN FOR FULL-YEAR 2015

FOURTH QUARTER OF 2015

• NET SALES amounted to MSEK 35.9 (39.9).
• OPERATIG PROFIT totalled MSEK 3.7 (6.6).
• PROFIT AFTER TAX amounted to MSEK 2.7 (5.4).
• PROFIT AFTER TAX PER SHARE was SEK 0.30 (0.59).
• CASH FLOW amounted to MSEK 0.0 (10.6).

ACCUMULATED 2015

• NET SALES amounted to MSEK 215.7 (135.2).
• OPERATING PROFIT totalled MSEK 63.1 (27.0).
• PROFIT AFTER TAX amounted to MSEK 49.0 (21.8).
• PROFIT AFTER TAX PER SHARE was SEK 5.38 (2.39).
• CASH FLOW amounted to MSEK 34.8 (16.9).

SIGNIFICANT EVENTS DURING THE FOURTH QUARTER:

• Probi FerroSorb, Probi’s product platform for better iron absorption, ready for launch.
• Launch of new Functional Food product with Seoul Dairy Cooperative, South Korea.

SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD:

• The Board proposes a total dividend of MSEK 9.1 (7.7), corresponding to SEK 1.00 (0.85) per share.

CEO COMMENTS ON THE OPERATIONS AND FUTURE DEVELOPMENT:

“In 2015, we reached a new milestone in the development of Probi, with net sales for the full-year totalling MSEK 215.6. This represents growth of 60% as compared with last year. Adjusted for currency effects, net sales amounted to MSEK 192.1, representing growth of 42%. We were able to increase our operating margin for the full-year from 20 to 29% despite doubling our sales and marketing staff in 2015. The growth in 2015 was mainly driven by a highly positive trend in the North American market, in which Pharmavite and NBTY, among others, conducted extensive launches of Probi’s products. Although deliveries, as expected, declined temporarily in the fourth quarter sales will increase again in the first quarter of 2016. Our order backlog indicates that net sales in Q1 2016 will be at least as high as in the strong first quarter of 2015. There are ongoing discussions regarding launches in new markets with high volume potential. As launch dates are still to be determined it is difficult to assess the extent to which this may affect 2016. Thus we expect continued growth for full-year 2016, albeit at a lower rate than in 2015,” says Peter Nählstedt, CEO of Probi.

INVITATION TO TELECONFERENCE (SWEDISH):

Time: Tuesday, 26 January 2016 at 10.00 a.m. Tel: +46 (0)8 505 564 68 Participants from Probi: Peter Nählstedt, CEO and Niklas Brandt, CFO. The presentation is available at www.probi.se and www.financialhearings.com

FOR FURTHER INFORMATION, PLEASE CONTACT:

Peter Nählstedt, CEO, Probi, tel: +46 (0)46-286 89 23 or +46 (0)723-86 99 83, e-mail: peter.nahlstedt@probi.se

Niklas Brandt, CFO, Probi, tel: +46 (0)46-286 89 26 or +46 (0)706-62 98 83, e-mail: niklas.brandt@probi.se

This information is such that Probi AB is required to disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 26 January 2016 at 8:45 a.m.

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

ABOUT PROBI

Probi AB is a Swedish publicly traded bioengineering company that develops effective and well-documented probiotics. Through its world-leading research, Probi has created a strong product portfolio in the gastrointestinal health and immune system niches. Probi’s products are available to consumers in more than 30 countries worldwide. Probi’s customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 216 in 2015. The Probi share is listed on NASDAQ OMX Stockholm, Small Cap. Probi has about 3,500 shareholders. Read more at www.probi.se.

Tags: